Medical Director at Seattle Cancer Treatment and Wellness Center
"Cancer patients often suffer from decreased appetite, weight loss and a host of other mental and physical problems," says Dr. Chen. "Their nutritional, mental and emotional states affect their immunity and overall outcome. It is quite clear that the treatment of cancer must involve an integration of all of these areas to be successful."
Dr. Nick Chen, Medical Director at Seattle Cancer Treatment and Wellness Center, strives to help his patients understand the full range of treatment options, not only for their disease, but for their overall quality of life.
Dr. Chen has been a pioneer in the use of low-dose, or “metronomic” chemotherapy, which fights tumors while drastically reducing the often debilitating side effects of traditional chemotherapy. He believes that combining this technique with natural and integrative oncology services provides a winning combination for his patients.
“I work side-by-side with naturopathic oncologists, practitioners of acupuncture and Chinese medicine, and mind-body specialists,” says Dr. Chen. “The communication between team members is prompt, continuous and complete.”
Board certified in medical oncology and internal medicine with a Ph.D. in immunology, Dr. Chen has provided patient care and studied medicine on three continents. He completed hematology fellowships at University Libre de Bruxelles in Belgium and Shanghai Medical University in China. He also earned a Ph.D. in immunology from the University of Iowa.
Dr. Chen completed an internal medicine residency at the University of Nebraska Medical Center, and a fellowship in medical oncology at Moffitt Cancer Treatment Center and Research Institute in Tampa, Florida, one of the top comprehensive cancer centers in the nation.
In 2002, Dr. Chen joined the integrative cancer treatment team at Seattle Cancer Treatment and Wellness Center. He has a special interest in research, currently serving as the Center’s Principle investigator in a clinical trial for the treatment of pancreatic cancer. He also focuses on innovative approaches to other, more difficult-to-treat cancers, such as lung cancer, metastatic melanoma, brain cancer, and relapsed lymphoma.
He is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Medical Association.